LRMR Company Profile and Key Details

Q: Who are the executives of LRMR?

Dr. Gopi Shankar M.B.A., Ph.D.Chief Devel. OfficerDr. Russell G. Clayton Sr., D.OScientific Advisory Board Chair & Chief Medical OfficerMr. John BermanVice President of Fin. & OperationsDr. Carole S. Ben-Maimon M.D.Chief Executive Officer, Pres & DirectorMs. Jennifer Spokes JohanssonVice President of Regulatory Affairs & CounselMr. Francis Michael ConwayVice President & ControllerMr. Michael Celano CPASec. & Chief Financial OfficerDr. Nancy M. RuizChief Medical OfficerMr. Francis Michael Conway C.P.A.Vice President & ControllerMr. Francis Michael Conway CPAVice President & Controller

NASDAQ : LRMR

Larimar Therapeutics

$3.83

At Close 4:00 PM

71.28

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Larimar Therapeutics, Inc. (LRMR) stock remained unchanged at $3.83 a share on NASDAQ. The stock opened at $3.84, fluctuating between $3.79 to $3.85 during the session.

Stock Snapshot

3.83

Prev. Close

397.87M

Market Cap

3.79

Day Low

-1.96

P/E Ratio

-1.95

EPS (TTM)

-0.77

Cash Flow per Share

3.84

Open

103.88M

Number of Shares

3.85

Day High

50.4%

Free Float in %

1.86

Book Value

391.89K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 04, 2026	3.82	3.85	3.79	3.83	391.89K
Sep 03, 2026	3.90	3.90	3.77	3.83	683.66K
Sep 02, 2026	3.96	4.08	3.82	3.87	515.26K
Sep 01, 2026	3.78	3.95	3.77	3.94	755.35K
Aug 31, 2026	3.98	4.00	3.81	3.82	1.07M
Aug 28, 2026	4.03	4.08	3.98	4.01	641.48K
Aug 27, 2026	4.16	4.16	4.02	4.05	672.76K
Aug 26, 2026	4.14	4.18	4.02	4.17	702.12K
Aug 25, 2026	4.08	4.24	4.08	4.16	1.08M
Aug 24, 2026	4.23	4.23	3.93	4.05	944.44K
Aug 21, 2026	4.20	4.21	4.09	4.18	699.11K
Aug 20, 2026	4.21	4.21	3.98	4.16	1.16M
Aug 19, 2026	4.19	4.34	4.17	4.25	1.23M
Aug 18, 2026	4.31	4.35	4.05	4.06	869.3K
Aug 17, 2026	4.33	4.42	4.30	4.32	882.72K
Aug 14, 2026	4.26	4.39	4.17	4.36	1.18M
Aug 13, 2026	4.38	4.47	4.23	4.27	1.5M
Aug 12, 2026	4.31	4.40	4.28	4.37	1.18M
Aug 11, 2026	4.04	4.39	4.02	4.31	1.66M
Aug 10, 2026	4.15	4.29	4.01	4.01	1.4M

Contact Details

Bala Cynwyd, PA 19004

United States

https://www.larimartx.com 844 511 9056

About Company

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

Stock Peers

ARGX

-20.31-1.93%

argenx SE$1,033.15 REGN

-15.75-1.87%

Regeneron Pharmaceuticals, Inc.$827.72 VRTX

-11.84-2.12%

Vertex Pharmaceuticals Incorporated$546.12 MDGL

-1.53-0.28%

Madrigal Pharmaceuticals, Inc.$541.08 UTHR

-2.63-0.54%

United Therapeutics Corporation$487.61 ONC

-4.42-1.22%

BeOne Medicines AG$358.26 KRYS

-13.23-3.56%

Krystal Biotech, Inc.$358.24 PRAX

-3.34-0.94%

Praxis Precision Medicines, Inc.$351.81 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

-4.14-1.43%

Ligand Pharmaceuticals Incorporated$285.60

Company Overview

The stock is currently mid-range between its 52-week high and low $2.71 and $6.42. With a market capitalization of about $397.87 million, Larimar Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.75). Key stats such as the average daily volume over the past year has been around 1.87 million shares, volume is running light vs its 52-week average. Headquartered in Bala Cynwyd, PA, Larimar Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Carole S. Ben-Maimon, the company employs approximately 71 people and listed since June 19, 2014. Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm.

Dividend & Fair Value

Larimar Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.12. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Larimar Therapeutics, Inc. generated EPS of -$1.93 over the past year. Five-year average earnings growth is 50.78%. Wall Street analysts project EPS growth of -0.62% annually over the next five years. The latest quarter delivered EPS of -$0.30. The next quarter is forecast at -$0.49. Next year's EPS is expected at -$39.69. Analyst sentiment is bullish. Analyst rating data shows there are 10 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $21.00 to $5.00. The high target offers 448.3% upside. The low target suggests 30.55% downside. The mean target is $11.33. This offers 195.82% upside. Larimar Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 04, 2026, missed forecasts by -21.35%. The prior quarter beat by -41.51%. Over the last six quarters, Apple has recorded several small beats. These include 9.52% in April 30, 2025.

Frequently Asked Questions

What is the current Larimar Therapeutics, Inc. (LRMR) stock price?

Larimar Therapeutics, Inc. (NASDAQ: LRMR) stock price is $3.83 in the last trading session. During the trading session, LRMR stock reached the peak price of $3.85 while $3.79 was the lowest point it dropped to. The percentage change in LRMR stock occurred in the recent session was 0% while the dollar amount for the price change in LRMR stock was $0.00.

LRMR's industry and sector of operation?

The NASDAQ listed LRMR is part of Biotechnology industry that operates in the broader Healthcare sector. Larimar Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of LRMR?

Dr. Gopi Shankar M.B.A., Ph.D.
Chief Devel. Officer
Dr. Russell G. Clayton Sr., D.O
Scientific Advisory Board Chair & Chief Medical Officer
Mr. John Berman
Vice President of Fin. & Operations
Dr. Carole S. Ben-Maimon M.D.
Chief Executive Officer, Pres & Director
Ms. Jennifer Spokes Johansson
Vice President of Regulatory Affairs & Counsel
Mr. Francis Michael Conway
Vice President & Controller
Mr. Michael Celano CPA
Sec. & Chief Financial Officer
Dr. Nancy M. Ruiz
Chief Medical Officer
Mr. Francis Michael Conway C.P.A.
Vice President & Controller
Mr. Francis Michael Conway CPA
Vice President & Controller

How LRMR did perform over past 52-week?

LRMR's closing price is 41.07% higher than its 52-week low of $2.72 where as its distance from 52-week high of $6.42 is -40.34%.

How many employees does LRMR have?

Number of LRMR employees currently stands at 71.

Link for LRMR official website?

Official Website of LRMR is: https://www.larimartx.com

How do I contact LRMR?

LRMR could be contacted at phone 844 511 9056 and can also be accessed through its website. LRMR operates from Three Bala Plaza East, Bala Cynwyd, PA 19004, United States.

How many shares of LRMR are traded daily?

LRMR stock volume for the day was 391.89K shares. The average number of LRMR shares traded daily for last 3 months was 1.87M.

What is the market cap of LRMR currently?

The market value of LRMR currently stands at $397.87M with its latest stock price at $3.83 and 103.88M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Larimar Therapeutics, Inc. (LRMR) stock remained unchanged at $3.83 a share on NASDAQ. The stock opened at $3.84, fluctuating between $3.79 to $3.85 during the session.

Stock Snapshot

3.83

Prev. Close

397.87M

Market Cap

3.79

Day Low

-1.96

P/E Ratio

-1.95

EPS (TTM)

-0.77

Cash Flow per Share

3.84

Open

103.88M

Number of Shares

3.85

Day High

50.4%

Free Float in %

1.86

Book Value

391.89K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 04, 2026	3.82	3.85	3.79	3.83	391.89K
Sep 03, 2026	3.90	3.90	3.77	3.83	683.66K
Sep 02, 2026	3.96	4.08	3.82	3.87	515.26K
Sep 01, 2026	3.78	3.95	3.77	3.94	755.35K
Aug 31, 2026	3.98	4.00	3.81	3.82	1.07M
Aug 28, 2026	4.03	4.08	3.98	4.01	641.48K
Aug 27, 2026	4.16	4.16	4.02	4.05	672.76K
Aug 26, 2026	4.14	4.18	4.02	4.17	702.12K
Aug 25, 2026	4.08	4.24	4.08	4.16	1.08M
Aug 24, 2026	4.23	4.23	3.93	4.05	944.44K
Aug 21, 2026	4.20	4.21	4.09	4.18	699.11K
Aug 20, 2026	4.21	4.21	3.98	4.16	1.16M
Aug 19, 2026	4.19	4.34	4.17	4.25	1.23M
Aug 18, 2026	4.31	4.35	4.05	4.06	869.3K
Aug 17, 2026	4.33	4.42	4.30	4.32	882.72K
Aug 14, 2026	4.26	4.39	4.17	4.36	1.18M
Aug 13, 2026	4.38	4.47	4.23	4.27	1.5M
Aug 12, 2026	4.31	4.40	4.28	4.37	1.18M
Aug 11, 2026	4.04	4.39	4.02	4.31	1.66M
Aug 10, 2026	4.15	4.29	4.01	4.01	1.4M

Contact Details

Bala Cynwyd, PA 19004

United States

https://www.larimartx.com 844 511 9056

About Company

Stock Peers

ARGX

-20.31-1.93%

argenx SE$1,033.15 REGN

-15.75-1.87%

Regeneron Pharmaceuticals, Inc.$827.72 VRTX

-11.84-2.12%

Vertex Pharmaceuticals Incorporated$546.12 MDGL

-1.53-0.28%

Madrigal Pharmaceuticals, Inc.$541.08 UTHR

-2.63-0.54%

United Therapeutics Corporation$487.61 ONC

-4.42-1.22%

BeOne Medicines AG$358.26 KRYS

-13.23-3.56%

Krystal Biotech, Inc.$358.24 PRAX

-3.34-0.94%

Praxis Precision Medicines, Inc.$351.81 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

-4.14-1.43%

Ligand Pharmaceuticals Incorporated$285.60

Company Overview

Technical Performance

LRMR has shown weak momentum, losing -1.54% over the past week and -23.81% over the past quarter, though year-to-date performance is down -16.01%. Short-term trend indicators are mixed aligned (SMA20 57.18%, SMA50 55.73%, SMA200 56.96%). The stock’s 14-day RSI is 72.34 (overbought), while the ATR of 0.49 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -14.02% below its high and over 242.86% above its low. Average 10-day trading volume of 723.24 thousand shares is below the 3-month average of 1.84 million, indicating normal recent market interest.

Valuation Metrics

Larimar Therapeutics, Inc. trades at a P/E ratio of -1.93, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.13 trading at moderately above to book value. The P/FCF stands at -2.55, also above market averages.

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Larimar Therapeutics, Inc. has 103.88 million shares outstanding. The public float is 57.90 million shares, elevated short interest at 18.13% of float. This equals 12.19 million shares. The short ratio is 6.64 days. Institutional investors hold 87.15% of the float. Insiders own 1.15%. Flynn James E holds 6.21 million shares, Hamilton Thomas Edward has 714.80 thousand shares and BEN-MAIMON CAROLE has 266.83 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Larimar Therapeutics has not generated any revenue. Returns are negative, with ROA at -38.51% and ROE at -45.21%.
On valuation metrics, Larimar Therapeutics trades at a P/E of -1.93, P/S of 0.00 and P/B of 3.13. The current ratio is 4.70 and quick ratio is 4.70. Debt-to-equity is 0.04, supported by a cash flow-to-debt ratio of -31.46.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Larimar Therapeutics posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $311.00K (margin 0.00%). Operating income was - $41.76M (margin 0.0%). Net income was- $36.95M (EPS - $0.84).
The company ended the quarter with $86.79M in cash and short-term investments, a total debt of $5.55M, and net debt of - $21.20M. Total assets were $95.94M, with equity of $81.72M. Financials further reflected weakness, with operating cash flow of - $33.46M, free cash flow of - $33.62M, and capital expenditures of - $164.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Larimar Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.18%, with price expected at $3.67 by September 17, 2026, within a range of $3.53 to $3.82 3-Month Outlook: Projected fall of -9.4%, reaching $3.47 by December 02, 2026, with a range of $3.32 to $3.63. 1-Year Outlook: Projected gain of 111.75%, with price at $8.11 by September 03, 2027, within a range of $0.21 to $9.45.

Key Takeaways

Larimar Therapeutics, Inc. (NASDAQ:LRMR) shares are down -16.01% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Larimar Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.93. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $14.97, suggesting 290.86% upside. Our AI forecast model points to short-term weakness (-4.18% over two weeks), a medium-term fall (-9.4% over three months), and a longer-term gain (111.75% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Larimar Therapeutics, Inc. (LRMR) stock price?

LRMR's industry and sector of operation?

Who are the executives of LRMR?

How LRMR did perform over past 52-week?

LRMR's closing price is 41.07% higher than its 52-week low of $2.72 where as its distance from 52-week high of $6.42 is -40.34%.

How many employees does LRMR have?

Number of LRMR employees currently stands at 71.

Link for LRMR official website?

Official Website of LRMR is: https://www.larimartx.com

How do I contact LRMR?

LRMR could be contacted at phone 844 511 9056 and can also be accessed through its website. LRMR operates from Three Bala Plaza East, Bala Cynwyd, PA 19004, United States.

How many shares of LRMR are traded daily?

LRMR stock volume for the day was 391.89K shares. The average number of LRMR shares traded daily for last 3 months was 1.87M.

What is the market cap of LRMR currently?

The market value of LRMR currently stands at $397.87M with its latest stock price at $3.83 and 103.88M of its shares outstanding.

Employees	71
Beta	0.75
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

LRMR Company Profile and Key Details

Larimar Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Dividend & Fair Value

Earnings & Analyst Outlook

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Valuation Metrics

Key Takeaways

Price Forecast & Outlook

Financial & Profitability Overview

Quarterly Financial Highlights